Succinylcholine
|
Rocuronium
|
|
Chemical
structure
|
Structurally
two acetyl choline molecules joined together
|
Aminosteroid
|
Classification
|
Depolarising
neuromuscular blocker
|
Non-depolarising
neuromuscular blocker
|
Fasciculation
|
Yes
( causes post-op myalgia)
|
No
|
Metabolism
|
·
Rapidly metabolised by
pseudocholinesterase
·
Duration of action prolonged in
Pseudocholinesterase deficiency
|
·
Eliminated primarily by liver and
slightly by kidney
·
Elimination half life longer as
compared to Sch.
|
Dosage
|
·
Used for intubation only now-a-days
·
1-1.5 mg/kg iv
·
4-5 mg/kg im (onset delayed)
|
·
Used for both intubation as well as
during maintenance
·
Intubation: 0.6-1.2mg /kg iv
·
Intubation: 1mg/kg im (infants) and
2mg/kg im (children) àonset delayed (3-6min)
·
Maintenance: 0.15 mg/kg every 20 mins
·
Continuous infusion: 5-12µg/kg/min
|
Onset
of action after iv induction dose (onset
to maximum twitch depression)
|
30-60secs
|
60-90
secs
|
Duration
of action
|
3-5
mins (phase 1 block)
|
·
Duration of action (duration to return to ≥ 25% of control
twitch height): 20-35 min
·
Clinical duration (duration to return to Train-of-four >0.9): 55-80 min
|
Reversal
with Sugammadex
|
Not
possible
|
Possible
Dose:
·
4 mg/kg iv when recovery has reached 1-2
post-tetanic counts
·
2 mg/kg iv if recovery has occurred upto
reappearance of T2
·
Immediate reversal: 16 mg/kg iv (recovery of T4/T1 ratio
to 0.9 by 1.5 min)
|
Systemic
effects
|
·
Causes bradycardia (especially when a second dose is given
after 3-8mins)
·
Hyperkalemia (increases K+ by 0.5 mEq/L)
·
Transient increase in intracranial, intraocular
and intragastric pressure
|
·
Mostly cardiostable
·
Mild vagolytic
|
Malignant
hyperthermia risk
|
Yes
|
No
|
Use
in burn patients
|
Avoid
beyond 2 days till 2 yrs after burn (risk
of hyperkalemia)
|
Can
be used safely
|
Apnoea
time (time available until critical
desaturation occurs in the absence of ventilation after administration of the
drug)
|
Less
(because of fasciculation which uses up oxygen)
|
More
|
Paediatric
usage
|
Usually
avoided especially in case of unknown/undiagnosed myopathy
|
Can
be used safely
|
Shelf
life
|
Stable
at room temperature for upto 14 days
|
Stable
at room temperature for upto 12 weeks
|
Sunday, May 31, 2015
Succinylcholine vs Rocuronium
Halothane vs Sevoflurane
Halothane
|
Sevoflurane
|
|
Chemical
structure
|
Halogenated
alkane
|
Fluorinated
methyl isopropyl ether
|
Odour
|
Both
drugs have a sweet odour
|
|
Preservative
for storage
|
Yes
(thymol)
|
No
|
Blood:
gas partition coefficient
|
High
(2.4)
Slower
rate of induction and recovery
|
Lower
(0.69)
Rapid
induction and recovery
|
MAC
|
0.75
(more
potent)
|
2
(less
potent)
|
CNS
effects
|
·
Hypoxic ventilator drive is severely
depressed by halothane.
·
Blunts autoregulation and increases cerebral
blood flow.
·
Maximum increase in CBF among
currently used volatile agents
|
Causes
an increase in CBF but to a lesser extent as compared to halothane.
|
CVS
effects
|
Causes
more severe cardiac depression
·
Direct myocardial depression resulting
in dose dependent decrease in BP
·
Decreases coronary blood flow due to
fall of BP
·
Attenuates Baroreceptor reflex thus
blunting the ability to maintain cardiac output by increasing heart rate
(like an inhalational β-blocker)
·
Sensitized heart to arrythmogenic
effects of catecholamines (epinephrine).
|
More
cardiac stable
·
Comparatively less depression of
myocardial contractility
·
Mild decrease in systemic vascular
resistance at equipotent dose
·
Does not sensitize the heart to catecholamines.
|
Hepatic
effects
|
·
Decreases hepatic blood flow
·
Hepatotoxic especially on frequent
repeated exposure—halothane hepatitis
|
·
Decreases portal venous flow but,
increases hepatic artery flowà so overall, hepatic blood
flow is maintained
|
Renal
effects
|
·
Decreases renal blood flow, GFR and
urinary output
·
Reduction in renal blood flow is more
as compared to reduction in GFR resulting in an increase in filtration
fraction
|
·
Slight decrease in renal blood flow,
GFR and urine output—comparatively to a lesser degree
·
Reacts with dry barium hydroxide
(baralyme) resulting in production of Compound A—found nephrotoxic in animal
studies.
|
On
children
|
·
Less emergence reaction
·
Less nausea/vomiting postoperative
|
·
More emergence reaction
·
Comparatively more nausea/vomiting postoperative
|
Upper
limit of concomitant epinephrine use
|
1.5
mcg/kg
|
4.5mcg/kg
|
Drug
interactions
|
·
Potentiates non-depolarising
neuromuscular blockers
·
Exaggerated myocardial depression when
used with beta blockers (eg propranolol) and calcium channel blockers (eg
verapamil)
·
Increased lability of BP when used in
patients receiving tricyclic antidepressants and monoamine oxidase inhibitors
·
Increased incidence of arrhythmia when
combined with aminophylline
|
·
Potentiates non-depolarising
neuromuscular blockers
·
Otherwise, significant drug
interaction among other commonly used drugs in clinical practice
|
Malignant
hyperthermia
|
Both
drugs can trigger an attack
|
Tuesday, May 26, 2015
i-gel vs LMA Classic
i-gel
|
LMA classic
|
2nd
generation Supraglottic device
|
1st
generation Supraglottic device
|
Cuffless device made of
medical grade thermoplastic elastomer
|
Cuffed device made of made of medical grade
silicone
|
An anatomic seal with
pharyngeal, laryngeal and perilaryngeal anatomy is created by conforming with
these structures at body temperature
|
Seal is achieved by
inflating the cuff
|
Single use device. So
increases the cost of therapy
|
Multiple use device. Can be used upto 40
times
|
It has an added drain
tube for passing gastric tube thus reducing risk of aspiration
|
No gastric drainage
facility
|
Chance of gastric
insufflations less
|
more
|
Easy insertion
technique—steep learning curve
|
Requires comparatively
more training and practice
|
Absence of cuff—so
insertion and removal rapid
|
Takes comparatively more time
|
Complete seal may take
some time to develop as the device warms up to body temperature
|
Seal is immediate after
inflation of the cuff
|
Less suitable for head
and neck procedures because of bulky rigid stem
|
Comparatively more suitable for such
procedures because of smaller diameter circular stem
|
Large transverse
diameter—prevents rotation in the mouth
|
Susceptible to rotation
|
Awake Intubation
First intubation for providing anaesthesia was reported by Dr. William
Macewan in 1878.
Preliminaries:
· Airway assessment
During the preoperative visit take a detailed history and physical examination to assess the difficulties that may come during the process and help in planning management.
Friday, May 15, 2015
Hofman degradation
Hofmann degradation is a
spontaneous process in plasma at normal pH and temperature and does not depend
on any circulating enzyme. In a Hofmann elimination reaction, a quaternary
ammonium group is converted to a tertiary amine by cleavage of a
carbon-nitrogen bond.
This is a pH- and
temperature-dependent reaction in which higher pH and temperature favor
elimination. Among drugs used in anesthesia, Atracurium
besylate and its 1R‐cis, 1R′‐cis isomer (cisatracurium) undergo Hofmann elimination. This unique pharmacological
property provides an organ‐independent degradation pathway.
Atracurium is a
bis-benzyltetrahydroisoquinolinium with isoquinolinium nitrogens connected by a
diester-containing hydrocarbon chain. The presence (in duplicate) of two-carbon
separations between quaternary nitrogen and ester carbonyl provides the basis
for a Hofmann elimination reaction.
The marketed form of atracurium has 10 isomers. These isomers have been separated into three geometric isomer groups that are designated cis-cis, cis-trans, and trans-trans according to their configuration about the tetrahydroisoquinoline ring system. The ratio of the cis-cis, cis-trans, and trans-trans isomers is approximately 10 : 6 : 1.
Atracurium is metabolised via Hofmann elimination and nonspecific ester hydrolysis (60%-90%). Laudanosine is the major metabolite of both pathways of metabolism of atracurium, with Hofmann elimination resulting in two molecules of laudanosine and ester hydrolysis resulting in one molecule of laudanosine for every molecule of atracurium that is metabolized.
Cisatracurium is the 1R cis–1′R cis isomer of atracurium and represents about
15% of the marketed atracurium mixture by weight but more than 50% in terms of
potency or neuromuscular blocking activity. Cisatracurium is metabolized by
Hofmann elimination. It is approximately four times as potent as atracurium,
but unlike atracurium, it does not cause release of histamine in the clinical
dose range.
In contrast to atracurium,
nonspecific plasma esterases do not seem to be involved in the clearance of cisatracurium.
Hofmann elimination accounts for 77% of the clearance of cisatracurium, whereas
renal clearance is responsible for another 16%. Because of the greater potency
of cisatracurium, laudanosine quantities produced by Hofmann elimination are 5
to 10 times lower than in the case of atracurium, thus making this not an issue
in practice.
Inverse Ratio Ventilation
Inverse
Ratio Ventilation (IRV) is a subset of (Pressure-controlled ventilation)PCV in
which inflation time is prolonged (In IRV, I:E ratio of 1:1, 2:1, or 3:1 may be
used)
A
decrease in inspiratory flow rate is used to prolong the time for lung
inflation.
This
lowers peak airway pressures but increases mean airway pressures. The prolonged
inflation
time can help prevent alveolar collapse.
However,
prolonged inflation times also increase the tendency for inadequate emptying of
the lungs, which can lead to hyperinflation and auto-PEEP.
Drawback - The tendency to produce auto-PEEP can lead to a decrease
in cardiac output
Indication - patients with ARDS who have refractory hypoxemia during conventional modes
of mechanical ventilation.
Monday, May 11, 2015
John Snow: Brief History
(1813
–1858)
Snow
was born in York, England. His neighbourhood was one of the poorest in the
city. His father used to work in the local coal yards.
He
was admitted as a member of the Royal College of Surgeons of
England and graduated from the University of London and was
later admitted to the Royal College of Physicians.
Work in Public Health:
- In 1850 he was also one of the founding members of the Epidemiological Society of London, formed in response to the cholera outbreak of 1849.
- He is considered as the father of modern epidemiology because of his work in tracing the source of a cholera outbreak in Soho, London. His findings inspired fundamental changes in the water and waste systems of London, which led to similar changes in other cities, and a significant improvement in general public health around the world.
Contributions to Anaesthesiology:
- He is also considered as the father of Anaesthesia. He was the 1st physician in England to take up full time interest in Ether for which he invented an inhaler. He was the 1st to scientifically investigate ether and the physiology of General Anaesthesia. In 1847, Snow published the 1st book on General Anaesthesia (On inhalation of Ether).
- When chloroform was discovered, he investigated it and also made an inhaler for it. He said that an inhaler should be used to deliver an inhaled agent to control its dose. His second book, ‘On Chloroform and other anaesthetics’ was published posthumously.
- He personally administered Chloroform to Queen Victoria when she gave birth to the last two of her nine children (Leopold and Beatrice) leading to a wider acceptance of Obstetric Anaesthesia.
Later life: He became a member of the Temperance Movement and lived for around a decade as a vegetarian and a Teetotaller. But later when his health deteriorated he returned to meat eating and drinking wine. He continued drinking boiling throughout his adult life.
Sunday, May 10, 2015
Subscribe to:
Posts (Atom)